Microenvironmental Regulation of Proliferation in Multicellular Spheroids Is Mediated through Differential Expression of Cyclin-Dependent Kinase Inhibitors
暂无分享,去创建一个
[1] R. Kerbel,et al. Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.
[2] S. Asa,et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.
[3] Herman Yeger,et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.
[4] Partial purification of a protein growth inhibitor from multicellular spheroids. , 1988, Biochemical and biophysical research communications.
[5] E. Choi,et al. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases , 1996, Nature.
[6] M. Tomonaga,et al. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. , 1995, Blood.
[7] James M. Roberts,et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.
[8] T. Tsuruo,et al. Up‐regulation of p27Kip1 Correlates Inversely with Anchorage‐independent Growth of Human Cancer Cell Lines , 1998, Japanese journal of cancer research : Gann.
[9] G. delle Fave,et al. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. , 2001, Human pathology.
[10] J. Freyer,et al. Regulation of growth saturation and development of necrosis in EMT6/Ro multicellular spheroids by the glucose and oxygen supply. , 1986, Cancer research.
[11] James P. Freyer,et al. Tumor growthin vivo and as multicellular spheroids compared by mathematical models , 1994, Bulletin of mathematical biology.
[12] A. Schönthal,et al. Activation of p53-p21 waf1 Pathway in Response to Disruption of Cell-Matrix Interactions* , 1997, The Journal of Biological Chemistry.
[13] J. Pines. Cyclin-dependent kinase inhibitors: the age of crystals. , 1997, Biochimica et biophysica acta.
[14] A. Giaccia,et al. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.
[15] F. Casagrande,et al. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. , 1998, Investigative ophthalmology & visual science.
[16] J. Lapointe,et al. A p18 mutant defective in CDK6 binding in human breast cancer cells. , 1996, Cancer research.
[17] J. Bartek,et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. , 1996, Cancer research.
[18] W. Lee,et al. Retinoblastoma protein and the cell cycle. , 1993, Current opinion in genetics & development.
[19] R. Sutherland. Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.
[20] G. Hannon,et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Freyer. Role of necrosis in regulating the growth saturation of multicellular spheroids. , 1988, Cancer research.
[22] Sutherland,et al. Tumor Hypoxia and Heterogeneity: Challenges and Opportunities for the Future. , 1996, Seminars in radiation oncology.
[23] Philip D. Jeffrey,et al. Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex , 1996, Nature.
[24] P. Beer-Romero,et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.
[25] R. Strausberg,et al. Transcriptional response to hypoxia in human tumors. , 2001, Journal of the National Cancer Institute.
[26] M. Kawada,et al. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway , 1997, Oncogene.
[27] Stephen J. Elledge,et al. Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.
[28] D. Franklin,et al. Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. , 1996, Molecular biology of the cell.
[29] J. Freyer,et al. Differential regulation of cyclin-dependent kinase inhibitors in monolayer and spheroid cultures of tumorigenic and nontumorigenic fibroblasts. , 1998, Cancer research.
[30] G. Strachan,et al. An early S phase checkpoint is regulated by the E2F1 transcription factor. , 1999, Biochemical and biophysical research communications.
[31] Yi-Song Wang,et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.
[32] G. Peters,et al. Induced Expression of p16INK4a Inhibits Both CDK4- and CDK2-Associated Kinase Activity by Reassortment of Cyclin-CDK-Inhibitor Complexes , 1999, Molecular and Cellular Biology.
[33] J. Massagué,et al. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 Kip1 ) of cyclin-dependent kinase 4 activation , 1994, Cell.
[34] M. Loda,et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. , 1998, The Journal of urology.
[35] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[36] C. O'keefe,et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.
[37] Y. Oda,et al. Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma , 2002 .
[38] James M. Roberts,et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.
[39] Tony Hunter,et al. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.
[40] F. Thaiss,et al. High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. , 1997, The American journal of physiology.
[41] T. Sano,et al. Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. , 1997, The Journal of clinical endocrinology and metabolism.
[42] Y. Oda,et al. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. , 2002, Cancer.
[43] J. Cheville,et al. Expression of p27kip1 in prostatic adenocarcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[44] A. Schönthal,et al. p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. , 2000, Cancer research.
[45] H. Sack,et al. Quiescent S-phase cells as indicators of extreme physiological conditions in human tumor xenografts. , 1999, International journal of radiation oncology, biology, physics.
[46] J. Cheville,et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.
[47] A. Takahashi,et al. p53-dependent induction of WAF1 by a low-pH culture condition in human glioblastoma cells. , 1997, Cancer research.
[48] R. Kerbel,et al. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. , 1994, Cold Spring Harbor symposia on quantitative biology.
[49] M. Bulyk,et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. , 1996, Cancer research.
[50] M. Loda,et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.
[51] A. Cittadini,et al. Reduced expression and altered subcellular localization of the cyclin‐dependent kinase inhibitor p27Kip1 in human colon cancer , 1999, Molecular carcinogenesis.
[52] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[53] S. Cowper,et al. Expression of p-27 (kip1) in nevi and melanomas. , 1999, The American Journal of dermatopathology.
[54] M. Loda,et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. , 1998, Cancer research.
[55] L. F. Fajardo,et al. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. , 1972, Journal of the National Cancer Institute.
[56] L. Hengst,et al. Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.
[57] P. Vaupel,et al. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia , 1997, Klinische Padiatrie.
[58] J P Freyer,et al. Rates of oxygen consumption for proliferating and quiescent cells isolated from multicellular tumor spheroids. , 1994, Advances in experimental medicine and biology.
[59] A. Borkowski,et al. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. , 1999, The American journal of pathology.
[60] Rolf Bjerkvig,et al. Spheroid Culture in Cancer Research , 1991 .
[61] Seongyong Kim,et al. Alterations of CDKN2 (MTS1/p16INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers , 1998, Experimental & Molecular Medicine.
[62] A. Cittadini,et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. , 1999, Cancer research.
[63] H. Nojima,et al. Induction of the Cyclin-dependent Kinase Inhibitor p21Sdi1/Cip1/Waf1 by Nitric Oxide-generating Vasodilator in Vascular Smooth Muscle Cells* , 1997, The Journal of Biological Chemistry.
[64] H. Koeffler,et al. p27/Kip1 mutation found in breast cancer. , 1996, Cancer research.
[65] G. Hannon,et al. p21-containing cyclin kinases exist in both active and inactive states. , 1994, Genes & development.
[66] L. Jin,et al. Aberrant p27kip1 expression in endocrine and other tumors. , 1997, The American journal of pathology.
[67] J. Steinkamp,et al. A new method for rapid and sensitive detection of bromodeoxyuridine in DNA-replicating cells. , 1987, Experimental cell research.
[68] A. Reymond,et al. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. , 1995, Oncogene.
[69] T. Hunter,et al. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.
[70] M. Roussel,et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.
[71] L. Cooper,et al. Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation. , 1995, Cancer research.
[72] D. Amadori,et al. p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions , 2002, The Journal of pathology.
[73] J. P. Freyer,et al. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. , 1986, British Journal of Cancer.
[74] David O. Morgan,et al. Principles of CDK regulation , 1995, Nature.
[75] A. Borkowski,et al. Loss of Cell Cycle Regulators p27Kip1 and Cyclin E in Transitional Cell Carcinoma of the Bladder Correlates with Tumor Grade and Patient Survival , 1999 .
[76] T. Graeber,et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status , 1994, Molecular and cellular biology.
[77] James M. Roberts,et al. Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.
[78] G. Bradley,et al. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. , 1998, The American journal of pathology.
[79] J P Freyer,et al. Regrowth kinetics of cells from different regions of multicellular spheroids of four cell lines , 1989, Journal of cellular physiology.
[80] M. Loda,et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.
[81] James M. Roberts,et al. Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle , 1996, Science.
[82] J. Massagué,et al. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. , 1997, Genes & development.
[83] L. Jin,et al. DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. , 1998, The American journal of pathology.
[84] L. Klotz,et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.
[85] J P Freyer,et al. Cellular energetics measured by phosphorous nuclear magnetic resonance spectroscopy are not correlated with chronic nutrient deficiency in multicellular tumor spheroids. , 1991, Cancer research.
[86] J P Freyer,et al. Decreased mitochondrial function in quiescent cells isolated from multicellular tumor spheroids , 1998, Journal of cellular physiology.
[87] M. Clayton,et al. Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. , 1997, British Journal of Cancer.
[88] J. LaBaer,et al. New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.
[89] K. Kinzler,et al. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.
[90] L. Green,et al. Role of Expression of Cell Cycle Inhibitor p27 and MIB‐1 in Predicting Lymph Node Metastasis in Male Breast Carcinoma , 2002, The breast journal.
[91] J. Nesland,et al. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.
[92] D. Louis,et al. Molecular Genetic Correlates of p16, cdk4, and pRb Immunohistochemistry in Glioblastomas , 1998, Journal of neuropathology and experimental neurology.